Rinvoq ER 45 MG tablet UU 28S
Ended Awarded Last action
- Contract number
- SPE2DR26F01N4
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $30,493
Award facts
- Contract value 100% obligated
- $30,492.73 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $30,492.73 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on December 4, 2025, with an ultimate completion date of December 5, 2025. This firm fixed-price, non-set-aside contract is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.999 billion prime vendor agreement running through December 2026 that serves as a comprehensive pharmaceutical support vehicle for military healthcare programs globally.
AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, delivers a broad range of medications and medical supplies to federal customers including the Defense Health Agency and U.S. Coast Guard. RINVOQ (upadacitinib), a Janus kinase inhibitor, is a specialty pharmaceutical used to treat conditions such as rheumatoid arthritis and other inflammatory disorders. The company's federal contract portfolio demonstrates consistent capability to meet competitive procurement requirements across multiple therapeutic domains, from brand-name and generic medications to vaccines and specialized medical devices, positioning it as a critical vendor for Department of Defense medical supply chain operations.
Quick answers
Who was awarded contract SPE2DR26F01N4?
SPE2DR26F01N4 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 4, 2025.
How much is contract SPE2DR26F01N4 worth?
The government has obligated $30,493 on SPE2DR26F01N4.
Is contract SPE2DR26F01N4 an order under another contract?
Yes. SPE2DR26F01N4 is a delivery order under SPE2DR25D2200, an indefinite delivery contract.
Was contract SPE2DR26F01N4 competed?
The extent of competition for SPE2DR26F01N4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award